Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma

References

• Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011;58:69–80.
   PubMed Web of Science ®Google Scholar
• Eng C. Microenvironmental protection in diffuse large-B-cell lymphoma. N Engl J Med 2008;359:2379–2381.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Stein HW, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 233–237.
   Google Scholar
• Hanzawa K, Momose S, Higashi M, et al. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk Lymphoma 2010;51:2054–2062.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Mikata A, Suzuki H, Ohkawa H. Immunohistochemical studies on B cell lymphomas with special reference to T cell infiltration and significance as a prognositic factor. Pathol Int 1988;38:47–58.
   Google Scholar
• Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251–4258.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• Bernd HW, Ziepert M, Thorns C, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma – analyses of cases from two prospective randomized clinical trials. Haematologica 2009;94:1569–1580.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Miller TP, Spier CM, et al. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988;72:436–441.
   PubMed Web of Science ®Google Scholar
• Miller TP, Lippman SM, Spier CM, et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988;82:370–372.
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721–728.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569–3577.
   PubMed Web of Science ®Google Scholar
• Lokesh KN, Sathyanarayanan V, Kuntegowdanahalli CL, et al. Primary diffuse large B-Cell lymphoma of testis: a single centre experience and review of literature. Urol Ann 2014;6:231–234.
   PubMedGoogle Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904–5912.
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425–3433.
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:e218–228.
   PubMed Web of Science ®Google Scholar
• Toellner KM, Luther SA, Sze DM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med 1998;187:1193–1204.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sozzani S, et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004;14:155–160.
   PubMed Web of Science ®Google Scholar
• Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007;19:217–223.
   PubMed Web of Science ®Google Scholar
• Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247–256.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193–200.
   PubMed Web of Science ®Google Scholar
• Glowala-Kosinska M, Chwieduk A, Nieckula J, et al. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol 2013;91:122–128.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 1057–1061.
   PubMed Web of Science ®Google Scholar
• Martorelli D, Muraro E, Merlo A, et al. Role of CD4 + cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 2010;29:371–402.
   PubMed Web of Science ®Google Scholar